DEA Officially Bans HHC, Hemp's Sketchy Cousin, Nationwide
Published Date: 5/4/2026
Rule
Summary
The DEA is giving hexahydrocannabinol (HHC) its own official spot on the list of Schedule I drugs, making it clear that HHC is controlled separately from other similar substances. This change starts May 4, 2026, and affects anyone making, selling, or using HHC, which stays illegal under federal law. No new fees or costs are introduced, but the update helps law enforcement and businesses know exactly where HHC stands.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
HHC Listed Separately in Schedule I
The DEA added hexahydrocannabinol (HHC) as its own specific Schedule I listing with DEA drug code 7220, effective May 4, 2026. HHC remains a Schedule I controlled substance (it was previously controlled under the tetrahydrocannabinols drug code 7370), so making, selling, or using HHC stays illegal under federal law.
DEA Can Set HHC Production Quotas
The rule lets DEA establish an aggregate production quota and grant individual manufacturing and procurement quotas specifically for HHC (hexahydrocannabinol). DEA-registered manufacturers of HHC, who previously received quotas under the tetrahydrocannabinols drug code, will receive quotas tied to the new HHC drug code.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
2026-08517 — Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
Starting May 1, 2026, the DEA officially puts four new substances—4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA—into Schedule I, meaning they’re now illegal to make, sell, or use without special permission. This affects anyone handling these chemicals, including researchers and businesses, who must follow strict rules or face serious penalties. The move aims to keep communities safer by cracking down on these risky drugs.
2026-08176 — Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements
Starting April 28, 2026, FDA-approved marijuana-based medicines move from the strictest drug category (Schedule I) to a less strict one (Schedule III). This change helps medical marijuana businesses get faster federal permits to make and sell these products legally. If you have a state medical marijuana license, you’ll find it easier and quicker to work with these medicines under new federal rules.
2026-08177 — Schedules of Controlled Substances: Rescheduling of Marijuana
The DEA is planning to move marijuana to Schedule III, which means it’s seen as less risky and easier to use medically. This change affects patients, doctors, and businesses, making marijuana more accessible and possibly boosting the market. A public hearing starts June 29, 2026, with chances to join by May 28, so get ready to have your say!
Previous / Next Documents
Previous: 2026-08580 — Removal of Standard of Identity for Canned “Tripe With Milk”
Starting June 3, 2026, canned “Tripe with Milk” won’t have a strict recipe to follow anymore. This change lets producers get creative while still making sure labels tell the truth. It’s good news for businesses who want more freedom without confusing customers or costing extra.
Next: 2026-08599 — Fisheries of the Northeastern United States; Summer Flounder Fishery; Quota Transfer From Virginia to New Jersey
Virginia is sharing some of its 2026 summer flounder fishing quota with New Jersey to help both states meet their fishing goals. This change kicks in on May 1, 2026, and lasts through the end of the year. Fishermen in both states should get ready for the updated limits, which keep the fishery fair and balanced without affecting overall catch limits.